Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab versus adalimumab in biologic-naive moderately-to-severely active Crohn's disease
2017-004209-41Phase 3Completed
- Sponsor
- Janssen Pharmaceutical
- Start
- May 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Crohn's disease comparing Ustekinumab arm with Adalimumab arm (2 arms). Primary endpoint: Clinical remission at Week 52. Started May 2018; status: completed.
02
Drugs
ustekinumabadalimumab
03
Conditions
Crohn's disease
Beyond the preview
Go deeper on 2017-004209-41.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-004209-41.